RESUMEN
Rab44 is a large Rab GTPase containing a Rab GTPase domain and some additional N-terminal domains. We recently used Rab44-deficient mice to demonstrate that Rab44 regulates granule exocytosis in mast cells and IgE-mediated anaphylaxis. In mouse mast cells, Rab44 is expressed as two isoforms, namely, the long and short forms; however, the characteristics of these two isoforms remain unknown. Here, we investigated secretion and localization of the human long Rab44 isoform and the two mouse isoforms and their mutants expressed in rat basophilic leukemia (RBL)-2H3 cells. Expression of the human long isoform and both mouse isoforms caused an increase in ß-hexosaminidase secretion. Confocal and quantitative analyses showed that both human and mouse long isoforms localized mainly to lysosomes while the mouse short isoform localized mainly to the ER. Live imaging with LysoTracker indicated that the size and number of LysoTracker-positive vesicles were altered by the various mutants. Ionomycin treatment partially altered localization of both long isoforms to the plasma membrane and cytosol, whereas it had little effect on colocalization of the short isoform with lysosomes. Mechanistically, both human and mouse Rab44 proteins interacted with vesicle-associated membrane protein 8 (VAMP8), a v-SNARE protein. Therefore, Rab44 isoforms similarly promote lysosomal exocytosis, but exhibit differential localization in mast cells.
Asunto(s)
Exocitosis , Lisosomas/metabolismo , Mastocitos/metabolismo , Proteínas de Unión al GTP rab/metabolismo , Animales , Retículo Endoplásmico/metabolismo , Humanos , Ratones , Ratones Noqueados , Transporte de Proteínas , Receptores de IgE/metabolismo , Proteínas SNARE/metabolismo , beta-N-Acetilhexosaminidasas/biosíntesis , Proteínas de Unión al GTP rab/genéticaRESUMEN
ß-N-Acetylhexosaminidases are glycoside hydrolases (GHs) acting on N-acetylated carbohydrates and glycoproteins with the release of N-acetylhexosamines. Members of the family GH20 have been reported to catalyze the transfer of N-acetylglucosamine (GlcNAc) to an acceptor, i.e., the reverse of hydrolysis, thus representing an alternative to chemical oligosaccharide synthesis. Two putative GH20 ß-N-acetylhexosaminidases, PhNah20A and PhNah20B, encoded by the marine bacterium Paraglaciecola hydrolytica S66T, are distantly related to previously characterized enzymes. Remarkably, PhNah20A was located by phylogenetic analysis outside clusters of other studied ß-N-acetylhexosaminidases, in a unique position between bacterial and eukaryotic enzymes. We successfully produced recombinant PhNah20A showing optimum activity at pH 6.0 and 50 °C, hydrolysis of GlcNAc ß-1,4 and ß-1,3 linkages in chitobiose (GlcNAc)2 and GlcNAc-1,3-ß-Gal-1,4-ß-Glc (LNT2), a human milk oligosaccharide core structure. The kinetic parameters of PhNah20A for p-nitrophenyl-GlcNAc and p-nitrophenyl-GalNAc were highly similar: kcat/KM being 341 and 344 mM-1 s-1, respectively. PhNah20A was unstable in dilute solution, but retained full activity in the presence of 0.5% bovine serum albumin (BSA). PhNah20A catalyzed the formation of LNT2, the non-reducing trisaccharide ß-Gal-1,4-ß-Glc-1,1-ß-GlcNAc, and in low amounts the ß-1,2- or ß-1,3-linked trisaccharide ß-Gal-1,4(ß-GlcNAc)-1,x-Glc by a transglycosylation of lactose using 2-methyl-(1,2-dideoxy-α-d-glucopyrano)-oxazoline (NAG-oxazoline) as the donor. PhNah20A is the first characterized member of a distinct subgroup within GH20 ß-N-acetylhexosaminidases.
Asunto(s)
Alteromonadaceae/enzimología , Organismos Acuáticos/enzimología , beta-N-Acetilhexosaminidasas/biosíntesis , Alteromonadaceae/genética , Organismos Acuáticos/genética , Biocatálisis/efectos de los fármacos , Estabilidad de Enzimas , Genoma Bacteriano , Glicosilación , Concentración de Iones de Hidrógeno , Cinética , Octoxinol/farmacología , Filogenia , Dominios Proteicos , Albúmina Sérica Bovina/farmacología , Cloruro de Sodio/farmacología , Especificidad por Sustrato/efectos de los fármacos , Temperatura , Factores de Tiempo , beta-N-Acetilhexosaminidasas/químicaRESUMEN
Alternatively activated macrophages are essential effector cells during type 2 immunity and tissue repair following helminth infections. We previously showed that Ym1, an alternative activation marker, can drive innate IL-1R-dependent neutrophil recruitment during infection with the lung-migrating nematode, Nippostrongylus brasiliensis, suggesting a potential role for the inflammasome in the IL-1-mediated innate response to infection. Although inflammasome proteins such as NLRP3 have important proinflammatory functions in macrophages, their role during type 2 responses and repair are less defined. We therefore infected Nlrp3 -/- mice with N. brasiliensis Unexpectedly, compared with wild-type (WT) mice, infected Nlrp3 -/- mice had increased neutrophilia and eosinophilia, correlating with enhanced worm killing but at the expense of increased tissue damage and delayed lung repair. Transcriptional profiling showed that infected Nlrp3 -/- mice exhibited elevated type 2 gene expression compared with WT mice. Notably, inflammasome activation was not evident early postinfection with N. brasiliensis, and in contrast to Nlrp3 -/- mice, antihelminth responses were unaffected in caspase-1/11-deficient or WT mice treated with the NLRP3-specific inhibitor MCC950. Together these data suggest that NLRP3 has a role in constraining lung neutrophilia, helminth killing, and type 2 immune responses in an inflammasome-independent manner.
Asunto(s)
Inflamasomas/fisiología , Enfermedades Pulmonares Parasitarias/inmunología , Proteína con Dominio Pirina 3 de la Familia NLR/fisiología , Nippostrongylus/inmunología , Infecciones por Strongylida/inmunología , Animales , Caspasa 1/fisiología , Quimiotaxis de Leucocito , Eosinofilia/etiología , Eosinofilia/inmunología , Furanos/farmacología , Compuestos Heterocíclicos de 4 o más Anillos , Inmunidad Innata , Indenos , Interleucina-4/farmacología , Lectinas/biosíntesis , Lectinas/genética , Pulmón/patología , Pulmón/fisiología , Enfermedades Pulmonares Parasitarias/complicaciones , Enfermedades Pulmonares Parasitarias/patología , Enfermedades Pulmonares Parasitarias/fisiopatología , Macrófagos Alveolares/enzimología , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Proteína con Dominio Pirina 3 de la Familia NLR/antagonistas & inhibidores , Proteína con Dominio Pirina 3 de la Familia NLR/deficiencia , Proteína con Dominio Pirina 3 de la Familia NLR/genética , Neutrófilos/inmunología , Regeneración , Infecciones por Strongylida/complicaciones , Infecciones por Strongylida/patología , Infecciones por Strongylida/fisiopatología , Sulfonamidas/farmacología , Sulfonas , Transcripción Genética , beta-N-Acetilhexosaminidasas/biosíntesis , beta-N-Acetilhexosaminidasas/genéticaRESUMEN
OBJECTIVES: Pethidine hydrochloride (PH) and fentanyl citrate (FC) are opioid receptor agonists commonly used to treat pain clinically. PH and FC have been reported to have a high potential for pseudoallergic effects, but the underlying mechanism has not been well studied. MRGPRX2 is a novel atypical opioid receptor that is mainly expressed in human mast cells and considered to mediate drug-induced pseudoallergic reactions. This study aimed to investigate the allergy effect of these two opioid receptor agonists and the possible association of MRGPRX2 with this response. METHODS: HEK293-MRGPRX2/CMC assay, molecular docking assay, calcium mobilization assay, the test of ß-hexosaminidase, histamine and cytokine release assay were performed in this article. KEY FINDINGS: PH but not FC induced LAD2 cell activation and degranulation dose-dependently. Histamine, tumour necrosis factor (TNF)-α, interleukin (IL)-8, monocyte chemotactic protein 1 (MCP-1) and macrophage inflammatory protein (MIP-1ß) levels were upregulated by PH, but not FC. The PH-induced activation of mast cell was MRGPRX2-dependent. CONCLUSIONS: PH but not FC activated mast cells, leading to degranulation mediated via MRGPRX2 receptors, which could be greatly significant in future clinical applications of opioid receptor drugs.
Asunto(s)
Degranulación de la Célula/efectos de los fármacos , Fentanilo/farmacología , Antagonistas de los Receptores Histamínicos/farmacología , Hipersensibilidad/tratamiento farmacológico , Citocinas/biosíntesis , Relación Dosis-Respuesta a Droga , Células HEK293 , Histamina/metabolismo , Humanos , Mastocitos/efectos de los fármacos , Simulación del Acoplamiento Molecular , Proteínas del Tejido Nervioso , Péptido Hidrolasas/efectos de los fármacos , Receptores Acoplados a Proteínas G , Receptores de Neuropéptido , Transducción de Señal/efectos de los fármacos , Regulación hacia Arriba , beta-N-Acetilhexosaminidasas/biosíntesisRESUMEN
Activation states of immune cells (among them, the so-called pro- or anti-inflammatory states) influence the pathogenesis of multiple sclerosis (MS). The neuropeptide calcitonin gene-related peptide (CGRP) can exert a pro- or anti-inflammatory role in a context-dependent manner. In mice CGRP was found to attenuate the development of experimental autoimmune encephalomyelitis (EAE, a common MS animal model). We analyzed CGRP effects on the expression of cytokines and markers of activation states, as well as its intracellular cascade, following intrathecal administration during EAE immunization. Real Time quantitative-PCR (RT-PCR) showed that IL-1beta and IL-6 (associated to a pro-inflammatory state in EAE), but also Ym1 (also known as Chil3), Arg1 and CD163 (associated to an anti-inflammatory state in EAE) were decreased in the encephalon (devoid of cerebellum). In the cerebellum itself, IL-1beta and Ym1 were decreased. TNF-alpha (associated to a pro-inflammatory state in EAE), but also IL-10 (associated to another type of anti-inflammatory state) and BDNF were unchanged in these two regions. No changes were detected in the spinal cord. Additional tendencies toward a change (as revealed by RT-PCR) were again decreases: IL-10 in the encephalon and Arg1 in the spinal cord. CGRP decreased percentage of Ym1+/CD68+ immunoreactive cells and cell density of infiltrates in the cervical spinal cord pia mater. Instead, Ym1 in the underlying parenchyma and at thoracic and lumbar levels, as well as Arg1, were unchanged. In cultured microglia the neuropeptide decreased Ym1, but not Arg1, immunoreactivity. Inducible NOS (iNOS) was unchanged in spinal cord microglia and astrocytes. The neuropeptide increased the activation of ERK1/2 in the astrocytes of the spinal cord and in culture, but did not influence the activation of ERK1/2 or p38 in the spinal cord microglia. Finally, in areas adjacent to infiltration sites CGRP-treated microglia showed a larger ramification radius. In conclusion, CGRP-induced EAE amelioration was associated to a concomitant, context-dependent decrease in the expression of markers belonging to both pro- or anti-inflammatory activation states of immune cells. It can be hypothesized that CGRP-induced EAE attenuation is obtained through a novel mechanism that promotes down-regulation of immune cell activation that facilitates the establishment of a beneficial environment in EAE provided possibly also by other factors.
Asunto(s)
Arginasa/antagonistas & inhibidores , Péptido Relacionado con Gen de Calcitonina/uso terapéutico , Encefalomielitis Autoinmune Experimental/tratamiento farmacológico , Interleucina-1beta/antagonistas & inhibidores , Interleucina-6/antagonistas & inhibidores , Lectinas/antagonistas & inhibidores , Receptores de Superficie Celular/antagonistas & inhibidores , beta-N-Acetilhexosaminidasas/antagonistas & inhibidores , Animales , Antígenos CD/biosíntesis , Antígenos CD/genética , Antígenos de Diferenciación Mielomonocítica/biosíntesis , Antígenos de Diferenciación Mielomonocítica/genética , Arginasa/biosíntesis , Arginasa/genética , Biomarcadores/metabolismo , Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Péptido Relacionado con Gen de Calcitonina/farmacología , Células Cultivadas , Encefalomielitis Autoinmune Experimental/genética , Encefalomielitis Autoinmune Experimental/metabolismo , Femenino , Expresión Génica , Interleucina-1beta/biosíntesis , Interleucina-1beta/genética , Interleucina-6/biosíntesis , Interleucina-6/genética , Lectinas/biosíntesis , Lectinas/genética , Ratones , Ratones Endogámicos C57BL , Receptores de Superficie Celular/biosíntesis , Receptores de Superficie Celular/genética , beta-N-Acetilhexosaminidasas/biosíntesis , beta-N-Acetilhexosaminidasas/genéticaRESUMEN
Macrophages play crucial roles in innate immune response and in the priming of adaptive immunity, and are characterized by their phenotypic heterogeneity and plasticity. Reprogramming intracellular metabolism in response to microenvironmental signals is required for M1/M2 macrophage polarization and function. Here we assessed the influence of iron on the polarization of the immune response in vivo and in vitro. Iron-enriched diet increased M2 marker Arg1 and Ym1 expression in liver and peritoneal macrophages, while iron deficiency decreased Arg1 expression. Under LPS-induced inflammatory conditions, low iron diet exacerbated the proinflammatory response, while the IL-12/IL-10 balance decreased with iron-rich diet, thus polarizing toward type 2 response. Indeed, in vitro macrophage iron loading reduced the basal percentage of cells expressing M1 co-stimulatory CD86 and MHC-II molecules. Further, iron loading of macrophages prevented the pro-inflammatory response induced by LPS through reduction of NF-κB p65 nuclear translocation with decreased iNOS, IL-1ß, IL-6, IL-12 and TNFα expression. The increase of intracellular iron also reduced LPS-induced hepcidin gene expression and abolished ferroportin down-regulation in macrophages, in line with macrophage polarization. Thus, iron modulates the inflammatory response outcome, as elevated iron levels increased M2 phenotype and negatively regulated M1 proinflammatory LPS-induced response.
Asunto(s)
Polaridad Celular , Hierro/metabolismo , Macrófagos Peritoneales/metabolismo , Animales , Arginasa/biosíntesis , Citocinas/biosíntesis , Regulación de la Expresión Génica/efectos de los fármacos , Inflamación/inducido químicamente , Inflamación/metabolismo , Inflamación/patología , Hierro/farmacología , Lectinas/biosíntesis , Lipopolisacáridos/toxicidad , Hígado/metabolismo , Hígado/patología , Macrófagos Peritoneales/patología , Ratones , Óxido Nítrico Sintasa de Tipo II/biosíntesis , beta-N-Acetilhexosaminidasas/biosíntesisRESUMEN
Stroke is a leading cause of disability and currently lacks effective therapy enabling long-term functional recovery. Ischemic brain injury causes local inflammation, which involves both activated resident microglia and infiltrating immune cells, including monocytes. Monocyte-derived macrophages (MDMs) exhibit a high degree of functional plasticity. Here, we determined the role of MDMs in long-term spontaneous functional recovery after middle cerebral artery occlusion in mice. Analyses by flow cytometry and immunocytochemistry revealed that monocytes home to the stroke-injured hemisphere., and that infiltration peaks 3 d after stroke. At day 7, half of the infiltrating MDMs exhibited a bias toward a proinflammatory phenotype and the other half toward an anti-inflammatory phenotype, but during the subsequent 2 weeks, MDMs with an anti-inflammatory phenotype dominated. Blocking monocyte recruitment using the anti-CCR2 antibody MC-21 during the first week after stroke abolished long-term behavioral recovery, as determined in corridor and staircase tests, and drastically decreased tissue expression of anti-inflammatory genes, including TGFß, CD163, and Ym1. Our results show that spontaneously recruited monocytes to the injured brain early after the insult contribute to long-term functional recovery after stroke. SIGNIFICANCE STATEMENT: For decades, any involvement of circulating immune cells in CNS repair was completely denied. Only over the past few years has involvement of monocyte-derived macrophages (MDMs) in CNS repair received appreciation. We show here, for the first time, that MDMs recruited to the injured brain early after ischemic stroke contribute to long-term spontaneous functional recovery through inflammation-resolving activity. Our data raise the possibility that inadequate recruitment of MDMs to the brain after stroke underlies the incomplete functional recovery seen in patients and that boosting homing of MDMs with an anti-inflammatory bias to the injured brain tissue may be a new therapeutic approach to promote long-term improvement after stroke.
Asunto(s)
Macrófagos , Monocitos , Recuperación de la Función , Accidente Cerebrovascular/fisiopatología , Animales , Anticuerpos Bloqueadores/farmacología , Antígenos CD/biosíntesis , Antígenos CD/genética , Antígenos de Diferenciación Mielomonocítica/biosíntesis , Antígenos de Diferenciación Mielomonocítica/genética , Conducta Animal/efectos de los fármacos , Quimera , Lateralidad Funcional , Infarto de la Arteria Cerebral Media/fisiopatología , Inflamación/patología , Lectinas/biosíntesis , Lectinas/genética , Macrófagos/patología , Masculino , Ratones , Ratones Endogámicos C57BL , Monocitos/patología , Plasticidad Neuronal/fisiología , Desempeño Psicomotor/efectos de los fármacos , Receptores CCR2/antagonistas & inhibidores , Receptores de Superficie Celular/biosíntesis , Receptores de Superficie Celular/genética , Recuperación de la Función/efectos de los fármacos , Accidente Cerebrovascular/patología , Factor de Crecimiento Transformador beta/biosíntesis , Factor de Crecimiento Transformador beta/genética , beta-N-Acetilhexosaminidasas/biosíntesis , beta-N-Acetilhexosaminidasas/genéticaRESUMEN
Macrophages represent a highly heterogenic cell population of the innate immune system, with important roles in the initiation and resolution of the inflammatory response. Purinergic signaling regulates both M1 and M2 macrophage function at different levels by controlling the secretion of cytokines, phagocytosis, and the production of reactive oxygen species. We found that extracellular nucleotides arrest macrophage differentiation from bone marrow precursors via adenosine and P2 receptors. This results in a mature macrophage with increased expression of M2, but not M1, genes. Similar to adenosine and ATP, macrophage growth arrested with LPS treatment resulted in an increase of the M2-related marker Ym1. Recombinant Ym1 was able to affect macrophage proliferation and could, potentially, be involved in the arrest of macrophage growth during hematopoiesis.
Asunto(s)
Inflamación/inmunología , Activación de Macrófagos/efectos de los fármacos , Macrófagos/efectos de los fármacos , Mielopoyesis/efectos de los fármacos , Agonistas del Receptor Purinérgico P1/farmacología , Agonistas del Receptor Purinérgico P2/farmacología , Receptores Purinérgicos P1/fisiología , Receptores Purinérgicos P2/fisiología , Adenina/farmacología , Nucleótidos de Adenina/farmacología , Animales , Ciclo Celular/efectos de los fármacos , División Celular/efectos de los fármacos , Células Cultivadas , Regulación de la Expresión Génica/efectos de los fármacos , Regulación de la Expresión Génica/inmunología , Inflamación/patología , Interferón gamma/farmacología , Interleucina-4/farmacología , Lectinas/biosíntesis , Lectinas/genética , Lectinas/farmacología , Lipopolisacáridos/farmacología , Macrófagos/clasificación , Macrófagos/citología , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Fenotipo , Antagonistas del Receptor Purinérgico P2/farmacología , Receptores Purinérgicos P2X7/biosíntesis , Receptores Purinérgicos P2X7/deficiencia , Receptores Purinérgicos P2X7/efectos de los fármacos , Receptores Purinérgicos P2X7/genética , Proteínas Recombinantes/farmacología , Transducción de Señal/efectos de los fármacos , Organismos Libres de Patógenos Específicos , beta-N-Acetilhexosaminidasas/biosíntesis , beta-N-Acetilhexosaminidasas/genética , beta-N-Acetilhexosaminidasas/farmacologíaAsunto(s)
Antígenos de Neoplasias/biosíntesis , Enfermedad de la Arteria Coronaria/enzimología , Vasos Coronarios/enzimología , Diabetes Mellitus Experimental/enzimología , Diabetes Mellitus Tipo 1/enzimología , Angiopatías Diabéticas/enzimología , Células Endoteliales/enzimología , Endotelio Vascular/enzimología , Histona Acetiltransferasas/biosíntesis , Hialuronoglucosaminidasa/biosíntesis , beta-N-Acetilhexosaminidasas/biosíntesis , Animales , Humanos , MasculinoRESUMEN
Cardiovascular disease is the primary cause of morbidity and mortality in diabetes, and endothelial dysfunction is commonly seen in these patients. Increased O-linked N-acetylglucosamine (O-GlcNAc) protein modification is one of the central pathogenic features of diabetes. Modification of proteins by O-GlcNAc (O-GlcNAcylation) is regulated by two key enzymes: ß-N-acetylglucosaminidase [O-GlcNAcase (OGA)], which catalyzes the reduction of protein O-GlcNAcylation, and O-GlcNAc transferase (OGT), which induces O-GlcNAcylation. However, it is not known whether reducing O-GlcNAcylation can improve endothelial dysfunction in diabetes. To examine the effect of endothelium-specific OGA overexpression on protein O-GlcNAcylation and coronary endothelial function in diabetic mice, we generated tetracycline-inducible, endothelium-specific OGA transgenic mice, and induced OGA by doxycycline administration in streptozotocin-induced type 1 diabetic mice. OGA protein expression was significantly decreased in mouse coronary endothelial cells (MCECs) isolated from diabetic mice compared with control MCECs, whereas OGT protein level was markedly increased. The level of protein O-GlcNAcylation was increased in diabetic compared with control mice, and OGA overexpression significantly decreased the level of protein O-GlcNAcylation in MCECs from diabetic mice. Capillary density in the left ventricle and endothelium-dependent relaxation in coronary arteries were significantly decreased in diabetes, while OGA overexpression increased capillary density to the control level and restored endothelium-dependent relaxation without changing endothelium-independent relaxation. We found that connexin 40 could be the potential target of O-GlcNAcylation that regulates the endothelial functions in diabetes. These data suggest that OGA overexpression in endothelial cells improves endothelial function and may have a beneficial effect on coronary vascular complications in diabetes.
Asunto(s)
Antígenos de Neoplasias/biosíntesis , Enfermedad de la Arteria Coronaria/enzimología , Vasos Coronarios/enzimología , Diabetes Mellitus Experimental/enzimología , Diabetes Mellitus Tipo 1/enzimología , Angiopatías Diabéticas/enzimología , Células Endoteliales/enzimología , Endotelio Vascular/enzimología , Histona Acetiltransferasas/biosíntesis , Hialuronoglucosaminidasa/biosíntesis , beta-N-Acetilhexosaminidasas/biosíntesis , Animales , Antígenos de Neoplasias/genética , Células Cultivadas , Conexinas/metabolismo , Enfermedad de la Arteria Coronaria/genética , Enfermedad de la Arteria Coronaria/fisiopatología , Vasos Coronarios/efectos de los fármacos , Vasos Coronarios/fisiopatología , Diabetes Mellitus Experimental/genética , Diabetes Mellitus Experimental/fisiopatología , Diabetes Mellitus Tipo 1/genética , Diabetes Mellitus Tipo 1/fisiopatología , Angiopatías Diabéticas/genética , Angiopatías Diabéticas/fisiopatología , Células Endoteliales/efectos de los fármacos , Endotelio Vascular/efectos de los fármacos , Endotelio Vascular/fisiopatología , Inducción Enzimática , Inhibidores Enzimáticos/farmacología , Glicosilación , Histona Acetiltransferasas/antagonistas & inhibidores , Histona Acetiltransferasas/genética , Humanos , Hialuronoglucosaminidasa/antagonistas & inhibidores , Hialuronoglucosaminidasa/genética , Masculino , Ratones Transgénicos , N-Acetilglucosaminiltransferasas/metabolismo , Neovascularización Fisiológica , Procesamiento Proteico-Postraduccional , Transducción de Señal , Vasodilatación , beta-N-Acetilhexosaminidasas/antagonistas & inhibidores , beta-N-Acetilhexosaminidasas/genética , Proteína alfa-5 de Unión ComunicanteRESUMEN
Oligosaccharide modification by N-acetylglucosaminyltransferase-V (GnT-V), which catalyses the formation of ß1,6 GlcNAc (N-acetylglucosamine) branches on N-glycans, is associated with various pathologies, such as cancer metastasis, multiple sclerosis and liver fibrosis. In this study, we demonstrated the involvement of GnT-V in the pathophysiology of scleroderma. High expression of GnT-V was observed in infiltrating cells in skin section samples from systemic and localized patients with scleroderma. Most of the infiltrating cells were T cells and macrophages, most of which were CD163(+) M2 macrophages. To determine the role of GnT-V in scleroderma, we next investigated skin sclerosis in GnT-V knockout (MGAT5(-/-) ) mice. Expression of GnT-V was also elevated in bleomycin (BLM)-injected sclerotic skin, and MGAT5(-/-) mice were resistant to BLM-induced skin sclerosis with reduced collagen type 1 α1 content, suggesting the biological significance of GnT-V in skin sclerosis. Furthermore, the number of CD163(+) M2 macrophages and CD3-positive T cells in BLM-induced skin sclerosis was significantly fewer in MGAT5(-/-) mice. In bone marrow-derived macrophages (BMDMs), IL-4-induced expressions of Fizz1 and Ym1 were significantly reduced in MGAT5(-/-) mice-derived BMDMs. Taken together, these results suggest the induction of GnT-V in skin sclerosis progression is possibly dependent on increased numbers of M2 macrophages in the skin, which are important for tissue fibrosis and remodelling.
Asunto(s)
Bleomicina/toxicidad , N-Acetilglucosaminiltransferasas/fisiología , Esclerodermia Sistémica/enzimología , Animales , Antígenos CD/análisis , Antígenos de Diferenciación Mielomonocítica/análisis , Complejo CD3/análisis , Colágeno Tipo I/deficiencia , Cadena alfa 1 del Colágeno Tipo I , Citocinas/farmacología , Humanos , Péptidos y Proteínas de Señalización Intercelular/biosíntesis , Péptidos y Proteínas de Señalización Intercelular/genética , Interleucina-4/farmacología , Lectinas/biosíntesis , Lectinas/genética , Macrófagos/química , Macrófagos/efectos de los fármacos , Macrófagos/enzimología , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , N-Acetilglucosaminiltransferasas/deficiencia , N-Acetilglucosaminiltransferasas/genética , Receptores de Superficie Celular/análisis , Esclerodermia Sistémica/inducido químicamente , Esclerodermia Sistémica/patología , Esclerosis , Piel/enzimología , Piel/patología , Subgrupos de Linfocitos T/química , Subgrupos de Linfocitos T/enzimología , beta-N-Acetilhexosaminidasas/biosíntesis , beta-N-Acetilhexosaminidasas/genéticaRESUMEN
Tissue resident macrophages have vital homeostatic roles in many tissues but their roles are less well defined in the heart. The present study aimed to identify the density, polarisation status and distribution of macrophages in the healthy murine heart and to investigate their ability to respond to immune challenge. Histological analysis of hearts from CSF-1 receptor (csf1-GFP; MacGreen) and CX3CR1 (Cx3cr1(GFP/+)) reporter mice revealed a sparse population of GFP positive macrophages that were evenly distributed throughout the left and right ventricular free walls and septum. F4/80+CD11b+ cardiac macrophages, sorted from myocardial homogenates, were able to phagocytose fluorescent beads in vitro and expressed markers typical of both 'M1' (IL-1ß, TNF and CCR2) and 'M2' activation (Ym1, Arg 1, RELMα and IL-10), suggesting no specific polarisation in healthy myocardium. Exposure to Th2 challenge by infection of mice with helminth parasites Schistosoma mansoni, or Heligmosomoides polygyrus, resulted in an increase in cardiac macrophage density, adoption of a stellate morphology and increased expression of Ym1, RELMα and CD206 (mannose receptor), indicative of 'M2' polarisation. This was dependent on recruitment of Ly6ChighCCR2+ monocytes and was accompanied by an increase in collagen content. In conclusion, in the healthy heart resident macrophages are relatively sparse and have a phagocytic role. Following Th2 challenge this population expands due to monocyte recruitment and adopts an 'M2' phenotype associated with increased tissue fibrosis.
Asunto(s)
Corazón/parasitología , Macrófagos/inmunología , Miocardio/inmunología , Esquistosomiasis mansoni/inmunología , Infecciones por Strongylida/inmunología , Animales , Antígenos de Diferenciación/metabolismo , Antígeno CD11b/metabolismo , Receptor 1 de Quimiocinas CX3C , Proteínas Fluorescentes Verdes/genética , Péptidos y Proteínas de Señalización Intercelular/biosíntesis , Lectinas/biosíntesis , Lectinas Tipo C/biosíntesis , Receptor de Manosa , Lectinas de Unión a Manosa/biosíntesis , Ratones , Ratones Noqueados , Nematospiroides dubius/inmunología , Fagocitosis/inmunología , Receptor de Factor Estimulante de Colonias de Macrófagos/genética , Receptores de Superficie Celular/biosíntesis , Receptores de Quimiocina/genética , Schistosoma mansoni/inmunología , Esquistosomiasis mansoni/parasitología , Infecciones por Strongylida/parasitología , Células Th2/inmunología , beta-N-Acetilhexosaminidasas/biosíntesisRESUMEN
Sandhoff disease (SD) is caused by deficiency of N-acetyl-ß-hexosaminidase (Hex) resulting in pathological accumulation of GM2 ganglioside in lysosomes of the central nervous system (CNS) and progressive neurodegeneration. Currently, there is no treatment for SD, which often results in death by the age of five years. Adeno-associated virus (AAV) gene therapy achieved global CNS Hex restoration and widespread normalization of storage in the SD mouse model. Using a similar treatment approach, we sought to translate the outcome in mice to the feline SD model as an important step toward human clinical trials. Sixteen weeks after four intracranial injections of AAVrh8 vectors, Hex activity was restored to above normal levels throughout the entire CNS and in cerebrospinal fluid, despite a humoral immune response to the vector. In accordance with significant normalization of a secondary lysosomal biomarker, ganglioside storage was substantially improved, but not completely cleared. At the study endpoint, 5-month-old AAV-treated SD cats had preserved neurological function and gait compared with untreated animals (humane endpoint, 4.4±0.6 months) demonstrating clinical benefit from AAV treatment. Translation of widespread biochemical disease correction from the mouse to the feline SD model provides optimism for treatment of the larger human CNS with minimal modification of approach.
Asunto(s)
Terapia Genética , Enfermedad de Sandhoff/terapia , Animales , Gatos , Dependovirus/genética , Dependovirus/inmunología , Progresión de la Enfermedad , Gangliósidos/metabolismo , Vectores Genéticos , Humanos , Inmunidad Humoral , Inyecciones Intraventriculares , Enfermedad de Sandhoff/patología , Transducción Genética , Resultado del Tratamiento , beta-N-Acetilhexosaminidasas/biosíntesis , beta-N-Acetilhexosaminidasas/genéticaRESUMEN
BACKGROUND: Mucopolysaccharidoses (MPS) are inborn metabolic disorders caused by a deficiency of glycosaminoglycan degrading enzymes. Although intravenous enzyme replacement therapy is a viable approach for the treatment of non-neuronopathic forms of MPS, its effectiveness in the central nervous system (CNS) is limited by the blood-brain barrier. Alternatively, enzyme replacement therapies and other therapies that directly target the brain represent approaches that circumvent the blood-brain barrier and, in the case of gene therapies, are intended to negate the need for repetitive dosing. METHODS: In the present study, gene therapy was targeted to the brains of young adult mice affected by mucopolysaccharidosis type IIIA (MPS IIIA) by bilateral delivery of two different therapeutic lentivirus vectors to the cerebral lateral ventricles. One vector expressed codon optimised murine sulphamidase, whereas the other co-expressed sulphamidase and sulfatase modifying factor-1. RESULTS: Six months after gene delivery, bladder distension was prevented in all treated animals, and behavioural deficits were improved. Therapeutic enzyme activity from the most efficacious vector, which was also the simpler vector, ranged from 0.5- to four-fold normal within the brains of treated animals, and the average amount of integrated vector ranged from 0.1-1 gene copies per cell. Consequently, levels of ganglioside and lysosomal ß-hexosaminidase, both of which are characteristically elevated in MPS IIIA, were significantly reduced, or were normalised. CONCLUSIONS: The present study demonstrates the efficacy of the intraventricular injection as a tool to target the brain with therapeutic genes in adult MPS IIIA mice, and provides evidence supporting this approach as a potentially effective means of treating CNS pathology in MPS IIIA patients.
Asunto(s)
Lentivirus/genética , Mucopolisacaridosis III/terapia , Animales , Encéfalo/enzimología , Encéfalo/patología , Gangliósido G(M2)/metabolismo , Gangliósido G(M3)/metabolismo , Terapia Genética , Humanos , Hidrolasas/biosíntesis , Hidrolasas/genética , Inyecciones Intraventriculares , Masculino , Aprendizaje por Laberinto , Ratones , Mucopolisacaridosis III/psicología , Transducción Genética , Resultado del Tratamiento , beta-N-Acetilhexosaminidasas/biosíntesis , beta-N-Acetilhexosaminidasas/genéticaRESUMEN
Pdcd4 has been known as a tumor-suppressor gene initially and is up-regulated during apoptosis. Surprisingly, we found that Pdcd4 was differentially expressed in the lung from E3 rats with AIPI, an animal model for asthma, but the precise role of Pdcd4 in AIPI still remained to be defined. In the present study, we first evaluated the expression of Pdcd4 in lung from control and AIPI rats with RT-qPCR, Western blot, and immunohistochemistry. Then, we investigated the effects of intervention of Pdcd4 on markers of macrophage alternative activation and airway remodeling. Upon challenging E3 rats with OVA, Pdcd4 was up-regulated in lung tissue with AIPI. Immunohistochemistry results showed that alveolar macrophages and airway epithelia expressed Pdcd4 protein. Overexpression of Pdcd4 in the rat alveolar macrophage cell line, NR8383 cells, increased the mRNA expression of arginase-1 and TGF-ß1, which are markers of macrophage alternative activation. In response to Pdcd4 RNAi in NR8383 cells, the mRNA expression of markers Fizz1, Ym1/2, arginase-1, and TGF-ß1 was decreased significantly. In addition, Pdcd4 RNAi in AIPI rats led to a decrease of the mRNA expression of Fizz1, Ym1/2, arginase-1, and TGF-ß1 in BALF cells. Finally, knockdown of Pdcd4 suppressed airway eosinophil infiltration, bronchus collagen deposition, and mucus production. Overall, these results suggest that Pdcd4 may be worthy of further investigation as a target for macrophage alternative activation and airway remodeling in allergic pulmonary inflammation.
Asunto(s)
Remodelación de las Vías Aéreas (Respiratorias)/fisiología , Proteínas Reguladoras de la Apoptosis/fisiología , Activación de Macrófagos/efectos de los fármacos , Macrófagos Alveolares/fisiología , Remodelación de las Vías Aéreas (Respiratorias)/inmunología , Animales , Proteínas Reguladoras de la Apoptosis/antagonistas & inhibidores , Proteínas Reguladoras de la Apoptosis/biosíntesis , Proteínas Reguladoras de la Apoptosis/genética , Arginasa/biosíntesis , Arginasa/genética , Asma/tratamiento farmacológico , Asma/inmunología , Asma/patología , Biomarcadores , Líquido del Lavado Bronquioalveolar , Línea Celular , Modelos Animales de Enfermedad , Regulación de la Expresión Génica/efectos de los fármacos , Pulmón/metabolismo , Pulmón/patología , Macrófagos Alveolares/efectos de los fármacos , Moco/metabolismo , Factor de Crecimiento Nervioso/biosíntesis , Factor de Crecimiento Nervioso/genética , Ovalbúmina/toxicidad , Interferencia de ARN , ARN Interferente Pequeño/farmacología , ARN Interferente Pequeño/uso terapéutico , Ratas , Bazo/metabolismo , Factor de Crecimiento Transformador beta1/biosíntesis , Factor de Crecimiento Transformador beta1/genética , beta-N-Acetilhexosaminidasas/biosíntesis , beta-N-Acetilhexosaminidasas/genéticaRESUMEN
BACKGROUND: Currently we observe a growing interest in human saliva as a non-invasive material for diagnosis and monitoring of general and oral diseases. METHODS: The aim of our study was adaptation of the Marciniak et al. (Marciniak J, Zalewska A, Popko J, Zwierz K, 2006, Clin Chem Lab Med 44: 933-937) method for determination of HEX and GLU activity in synovial fluid, and for determination of: HEX and GLU, as well as MAN, GAL, and FUC activity in human saliva. RESULTS: Under optimal conditions, 10 µl of saliva for HEX, and 30 µl for GLU, MAN, GAL and FUC, were sufficient for determination of human salivary exoglycosidases activity with variation coefficient ranging from 0.89 for GLU to 0.99 for GAL. CONCLUSION: The adapted method for exoglycosidases activity determination in human saliva is sufficiently sensitive and precise to use in clinical diagnosis.
Asunto(s)
Enfermedades Periodontales/diagnóstico , alfa-L-Fucosidasa , alfa-Manosidasa , beta-Galactosidasa , beta-N-Acetilhexosaminidasas , Adulto , Artritis Reumatoide/patología , Femenino , Estudios de Asociación Genética , Humanos , Lisosomas/enzimología , Enfermedades Periodontales/enzimología , Enfermedades Periodontales/patología , Saliva/enzimología , alfa-L-Fucosidasa/biosíntesis , alfa-Manosidasa/biosíntesis , beta-Galactosidasa/biosíntesis , beta-N-Acetilhexosaminidasas/biosíntesisRESUMEN
Carbohydrate response element-binding protein (ChREBP) is a transcription factor responsible for carbohydrate metabolism in the liver. However, the role of ChREBP in diabetic nephropathy has not been elucidated. Thus, we investigated the role of ChREBP in mesangial cells in diabetic nephropathy. Treatment with 25 mM glucose (high glucose; HG) increased cellular O-GlcNAc and O-GlcNAcylated ChREBP in mesangial cells compared with normal 5.5 mM glucose. O-(2-acetamido-2-deoxy-D-glucopyranosylidene) amino N-phenylcarbamate (PUGNAc), a drug that increases O-GlcNAc, augmented the expression of ChREBP targets, whereas DON, a drug that decreases O-GlcNAc and O-GlcNAcase overexpression, mitigated the increase with HG. O-GlcNAc augmented the protein stability, transcriptional activity, and nuclear translocation of ChREBP. HG treatment also stimulated lipid accumulation and the contents of triglyceride and cholesterol in mesangial cells. In addition, HG triggered expression of hypoxia-inducible factor 1-α, vascular endothelial growth factor, and extracellular matrix components related to nephrosclerosis. The ChREBP mutant, W130A, did not exhibit HG-induced lipid accumulation and fibrotic proteins, suggesting that the Trp-130 residue in the MCR3 domain is important in the development of glomerulosclerosis. O-GlcNAcylated ChREBP was elevated in mesangium cells of streptozotocin-induced diabetic rats. In conclusion, HG increased the O-GlcNAcylated ChREBP level, which resulted in lipid accumulation and up-regulation of fibrotic proteins in mesangial cells. These effects may lead mesangial cells to an ultimately pathological state.
Asunto(s)
Factores de Transcripción Básicos con Cremalleras de Leucinas y Motivos Hélice-Asa-Hélice/metabolismo , Nefropatías Diabéticas/metabolismo , Glucosa/farmacología , Lipogénesis/efectos de los fármacos , Células Mesangiales/metabolismo , Edulcorantes/farmacología , Acetilglucosamina/análogos & derivados , Acetilglucosamina/farmacología , Animales , Factores de Transcripción Básicos con Cremalleras de Leucinas y Motivos Hélice-Asa-Hélice/genética , Colesterol/biosíntesis , Colesterol/genética , Diabetes Mellitus Experimental/genética , Diabetes Mellitus Experimental/metabolismo , Diabetes Mellitus Experimental/patología , Nefropatías Diabéticas/inducido químicamente , Nefropatías Diabéticas/genética , Nefropatías Diabéticas/patología , Fibrosis/inducido químicamente , Fibrosis/genética , Fibrosis/metabolismo , Fibrosis/patología , Regulación Enzimológica de la Expresión Génica/efectos de los fármacos , Regulación Enzimológica de la Expresión Génica/genética , Células HEK293 , Humanos , Células Mesangiales/patología , Oximas/farmacología , Fenilcarbamatos/farmacología , Ratas , Triglicéridos/biosíntesis , Triglicéridos/genética , beta-N-Acetilhexosaminidasas/biosíntesisRESUMEN
OBJECTIVE: There is increasing evidence that the addition of O-linked N-acetylglucosamine (O-GlcNAc) to proteins plays an important role in cell signaling pathways. In chondrocytes, accumulation of O-GlcNAc-modified proteins induces hypertrophic differentiation. Osteoarthritis (OA) is characterized by cartilage degradation, and hypertrophic-like changes in hyaline chondrocytes. However, the mechanisms responsible for these changes have not been described. Our aim was to study whether O-GlcNAcylation and the enzymes responsible for this modification are dysregulated in the cartilage of patients with knee OA and whether interleukin-1 could induce these modifications in cultured human OA chondrocytes (HOC). DESIGN: Human cartilage was obtained from patients with knee OA and from age and sex-matched healthy donors. HOC were cultured and stimulated with the catabolic cytokine IL-1α. Global protein O-GlcNAcylation and the synthesis of the key enzymes responsible for this modification, O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA), were assessed by western blot. RESULTS: OA was associated with a 4-fold increase in the global O-GlcNAcylation in the cartilage. OA cartilage showed a re-distribution of the OGT and OGA isoforms, with a net increase in the presence of both enzymes, in comparison to healthy cartilage. In HOC, IL-1α stimulation rapidly increased O-GlcNAcylation and OGT and OGA synthesis. CONCLUSIONS: Our results indicate that a proinflammatory milieu could favor the accumulation of O-GlcNAcylated proteins in OA cartilage, together with the dysregulation of the enzymes responsible for this modification. The increase in O-GlcNAcylation could be responsible, at least partially, for the re-expression of hypertrophic differentiation markers that have been observed in OA.
Asunto(s)
Acetilglucosamina/metabolismo , Cartílago Articular/metabolismo , Osteoartritis de la Rodilla/metabolismo , Modificación Traduccional de las Proteínas/fisiología , Acilación , Adulto , Cartílago Articular/patología , Estudios de Casos y Controles , Diferenciación Celular/fisiología , Células Cultivadas , Condrocitos/efectos de los fármacos , Condrocitos/metabolismo , Femenino , Humanos , Mediadores de Inflamación/farmacología , Interleucina-1/farmacología , Isoenzimas/biosíntesis , Masculino , Persona de Mediana Edad , N-Acetilglucosaminiltransferasas/biosíntesis , Osteoartritis de la Rodilla/patología , Modificación Traduccional de las Proteínas/efectos de los fármacos , beta-N-Acetilhexosaminidasas/biosíntesisRESUMEN
Lysosomes are membrane-enclosed organelles containing acid hydrolases. They mediate a variety of physiological processes, such as cellular clearance, lipid homeostasis, energy metabolism and pathogen defence. Lysosomes can secrete their content through a process called lysosome exocytosis in which lysosomes fuse with the plasma membrane realising their content into the extracellular milieu. Lysosomal exocytosis is not only responsible for the secretion of lysosomal enzymes, but it also has a crucial role in the plasma membrane repair. Recently, it has been demonstrated that lysosome response to the physiologic signals is regulated by the transcription factor EB (TFEB). In particular, lysosomal secretion is transcriptionally regulated by TFEB which induces both the docking and fusion of lysosomes with the plasma membrane. In this work we demonstrated that TFEB nuclear translocation is accompanied by an increase of mature glycohydrolases ß-hexosaminidase and ß-galactosidase on cell surface. This evidence contributes to elucidate an unknown TFEB biological function leading the lysosomal glycohydrolases on plasma membrane.
Asunto(s)
Factores de Transcripción Básicos con Cremalleras de Leucinas y Motivos Hélice-Asa-Hélice/fisiología , Lisosomas/enzimología , beta-Galactosidasa/biosíntesis , beta-N-Acetilhexosaminidasas/biosíntesis , Membrana Celular/metabolismo , Exocitosis , Células HEK293 , Humanos , Transporte de ProteínasRESUMEN
Murine macrophages are activated by interferon-γ (IFN-γ) and/or Toll-like receptor (TLR) agonists such as bacterial endotoxin (lipopolysaccharide [LPS]) to express an inflammatory (M1) phenotype characterized by the expression of nitric oxide synthase-2 (iNOS) and inflammatory cytokines such as tumor necrosis factor-α (TNF-α) and interleukin (IL)-12. In contrast, Th2 cytokines IL-4 and IL-13 activate macrophages by inducing the expression of arginase-1 and the anti-inflammatory cytokine IL-10 in an IL-4 receptor-α (IL-4Rα)-dependent manner. Macrophages activated in this way are designated as "alternatively activated" (M2a) macrophages. We have shown previously that adenosine A2A receptor (A(2A)R) agonists act synergistically with TLR2, TLR4, TLR7, and TLR9 agonists to switch macrophages into an "M2-like" phenotype that we have termed "M2d." Adenosine signaling suppresses the TLR-dependent expression of TNF-α, IL-12, IFN-γ, and several other inflammatory cytokines by macrophages and induces the expression of vascular endothelial growth factor (VEGF) and IL-10. We show here using mice lacking a functional IL-4Rα gene (IL-4Rα(-/-) mice) that this adenosine-mediated switch does not require IL-4Rα-dependent signaling. M2d macrophages express high levels of VEGF, IL-10, and iNOS, low levels of TNF-α and IL-12, and mildly elevated levels of arginase-1. In contrast, M2d macrophages do not express Ym1, Fizz1 (RELM-α), or CD206 at levels greater than those induced by LPS, and dectin-1 expression is suppressed. The use of these markers in vivo to identify "M2" macrophages thus provides an incomplete picture of macrophage functional status and should be viewed with caution.